RPLM-RS: Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL (clinicaltrials.gov) - Sep 22, 2026 - P2 | N=23 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P2 trial • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Richter's Syndrome • BCL2
|